Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Spatially structured chip-based cognition platform for molecular mapping and therapy induced neurocognitive dysfunction modelling in pediatric medulloblastoma.

Project description

Modelling brain damage with organ-on-chip technology

Medulloblastoma is the most common malignant brain tumour in children. While survival rates have improved, treatment with radiation and chemotherapy frequently causes lasting damage to the developing brain, impairing cognition and quality of life. It remains poorly understood which brain regions are most vulnerable and why. With the support of the Marie Skłodowska-Curie Actions programme, the SCOPE project will develop a human stem cell-derived organoid-on-a-chip platform that models the developing brain and spinal cord in a microfluidic device. By exposing this system to cancer therapies and analysing molecular changes using spatial proteomics and AI, researchers will map treatment-induced neurotoxicity. The goal is to identify molecular pathways underlying cognitive dysfunction in paediatric brain cancer survivors.

Objective

SCOPE (Spatially structured Chip-based cOgnition Platform for molecular mapping and thErapy-induced neurocognitive dysfunction modelling in pediatric medulloblastoma) aims to create a human-relevant organoid-on-a-chip system to study how craniospinal irradiation and chemotherapy disrupt neurodevelopment and cognitive function in childhood Group 3 medulloblastoma. Its central objective is to model brain region-specific vulnerabilities to therapy and identify molecular pathways underlying treatment-induced neurotoxicity.

The project will integrate induced Pluripotent Stem Cells-derived cerebellar and 3-dimensional bioprinted spinal organoids with tumor spheroids in microfluidic chips engineered for precise spatial and temporal control. This platform will enable real-time mapping of therapy-induced cellular and molecular alterations across cognitive circuits. Spatial proteomic analysis through advanced multiplex imaging will reveal protein-level signatures of neurodevelopmental disruption, while Artificial Intelligence-driven analysis will model spatiotemporal patterns of injury and predict long-term impact on cognition. The combined approach of organoid biology, chip engineering, and computational modeling will generate a multidimensional understanding of therapy-driven changes.

SCOPE is fully aligned with the Marie Skłodowska-Curie Actions (MSCA) work program by tackling the urgent challenge of protecting neurocognitive health in pediatric cancer survivors. It will train the fellow in organoid culture, microfluidics, proteomics, imaging, and AI-based systems biology, providing strong interdisciplinary expertise. Beyond advancing mechanistic insights, SCOPE establishes a developmentally relevant preclinical platform that strengthens EU research capacity, supports translational innovation in pediatric oncology, and contributes to reducing treatment-related disability in children surviving brain cancer.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2025-PF

See all projects funded under this call

Coordinator

UNIVERSITY OF LIMERICK
Net EU contribution
€ 268 568,64
Address
NATIONAL TECHNOLOGICAL PARK, PLASSEY
- Limerick
Ireland
Region
Ireland Southern Mid-West
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data